The Panodyne COVID-19 Antigen (Saliva) Rapid Lateral Flow Lollipop Style Test Kit, is intended for Health Professional Use in various settings to help identify whether, for example, visitors to those in care homes (at the time of testing) have COVID-19 (Coronavirus) – even if no obvious symptoms are present.

We recommend you read the Official Government Guidance regarding SARS-COV-2 Lateral Flow Tests here.

Panodyne COVID-19 tests will detect the new Omicron Variant. Panodyne will continue to keep an eye on the variation of international novel coronavirus strains and will carry out verifications ot ensure they continue to stay abreast of detecting this evolving virus. For more information see lower down the page.

It’s quick and accurate. The point of care test uses a saliva sample to detect the presence of the antigen produced by the body’s immune system, and a positive or negative result is visible within 15 minutes of testing, with an accuracy rate of over 95%.

Most tests require both a nose and throat swab in order to work correctly, however this lollipop style test card has been specifically formulated with an absorbent tip to collect the saliva sample so there's no pain or discomfort. It's also easier to use for vulnerable people or those with a disability.

These tests can be administered to both Adults & Children.

The test kit works very quickly, requires no specialist equipment, is easy to use, and test results are easy to read. It can be self-administered under supervision by trained staff, a healthcare professional, company nurse, or occupational health personnel as they do not require any medical training. Also, please note that if you are experiencing any COVID-19 symptoms, you must follow Government guidelines in terms of isolating and testing.

Please note that this test is not intended for home use.

HS Code: 3822001000

A recent article was published on the National Health Executive website about Panodyne tests which can be read here.

Panodyne sets the industry standards for unrivalled customer care and excellent client services from order to delivery, providing prompt replies and swift resolution to any queries. All Panodyne products are fully accredited and CE certified and registered with the MHRA where applicable.

With over 20 years of expertise, Panodyne is a well-established and trusted UK manufacturer with full ISO 9001:2015 and ISO:13845 quality management system accreditations. Its production facilities are regulated and audited under the strictest standards to guarantee high quality consistency and product availability, while products are also independently tested by global testing agencies such as SGS and Intertek. All products and medical devices are researched, designed, and formulated in the UK and tested to the highest European standards to meet all legal requirements.

On 26th of November, The Omicron variant was included as a fifth VOC (Variants of concern) by the World Health Organisation. Before this, the four known variants were Alpha, Beta, Gamma, Delta. SARS-CoV-2 Coronavirus Variant OMICRON Variants of Concern (VOC) Working definition: A SARS-CoV-2 variant that meets the definition of a VOI (see below) and, through a comparative assessment, has been demonstrated to be associated with one or more of the following changes at a degree of global public health significance:

Increase in transmissibility or detrimental change in COVID-19 epidemiology; or Increase in virulence or change in clinical disease presentation; or Decrease in effectiveness of public health and social measures or available diagnostics, vaccines, therapeutics.

The Omicron B.1.1.529 variant may have a potent infectivity of 500 percent. It is currently the most dangerous novel Coronavirus variant in the world Worldwide, omicron has been reported in South Africa, Israel, Botswana, Belgium and Hong Kong.

In view of the validity of the detection of novel Coronavirus variants, Panodyne® has completed the detection of the latest mutations (including but not limited to Alpha (B.1.1.7), Beta (B.1.351), Gamma (p.1) and Delta) with antigen detection reagents (B.1.617.2), Lambda (C.37), Kappa (B.1.617.1), Eta (B.1525), Lota (B.1526), Mu (B.1.621), Zeta (P.2), Omicron (B.1.1.529), etc.), The testing and theoretical reasoning results confirm detection of Omicron was not missed, ensuring the accuracy and sensitivity of novel Coronavirus antigen detection reagents.